BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25122428)

  • 21. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
    Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
    Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
    Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
    Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
    Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
    Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
    Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
    Heavey S; O'Byrne KJ; Gately K
    Cancer Treat Rev; 2014 Apr; 40(3):445-56. PubMed ID: 24055012
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Amato O; Buisseret L; Gebhart G; Plouznikoff N; Larsimont D; Awada A; Piccart M; Aftimos P
    Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36863843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
    Hou MM; Liu X; Wheler J; Naing A; Hong D; Coleman RL; Tsimberidou A; Janku F; Zinner R; Lu K; Kurzrock R; Fu S
    Oncotarget; 2014 Nov; 5(22):11168-79. PubMed ID: 25426553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.
    Wojtalla A; Fischer B; Kotelevets N; Mauri FA; Sobek J; Rehrauer H; Wotzkow C; Tschan MP; Seckl MJ; Zangemeister-Wittke U; Arcaro A
    Clin Cancer Res; 2013 Jan; 19(1):96-105. PubMed ID: 23172887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
    Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
    Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
    [No Abstract]   [Full Text] [Related]  

  • 36. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
    Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
    Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
    Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
    Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.